Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers

Assadi, Majid; Javad Rekabpour, Seyed; Jafari, Esmail; Divband, Ghasemali; Nikkholgh, Babak; Amini, Hamidreza; Kamali, Hassan; Ebrahimi, Sakineh; Shakibazad, Nader; Jokar, Narges; Nabipour, Iraj; Ahmadzadehfar, Hojjat

doi:10.1097/rlu.0000000000003810

Public

Feasibility and Therapeutic Potential of 177Lu–Fibroblast Activation Protein Inhibitor–46 for Patients With Relapsed or Refractory Cancers

Published in Clinical Nuclear Medicine • Jul 15, 2021

Authors:

Majid Assadi

Seyed Javad Rekabpour

Esmail Jafari

Abstract

INTRODUCTION: Fibroblast activation protein (FAP) is a member of the serine protease family and has a high expression in the stroma of approximately 90% of epithelial malignancies. The present investigation aimed to assess the feasibility, safety, and dosimetry data of 177Lu-FAPI-46 in diverse malig...

Subject

Medicine

Common Terminology Criteria for Adverse Events

Adverse effect

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!